Rokos Capital Management LLP Arrowhead Pharmaceuticals, Inc. Transaction History

Rokos Capital Management LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$21.87 - $28.24 $6.32 Million - $8.17 Million	-289,164 Reduced 23.53%	939,984 $24.4 Million
Q4 2023 Feb 14, 2024	SELL	$21.2 - $31.03 $9.47 Million - $13.9 Million	-446,773 Reduced 26.66%	1,229,148 $37.6 Million
Q1 2023 May 15, 2023	BUY	$23.68 - $38.51 $30.2 Million - $49.1 Million	1,274,999 Added 318.02%	1,675,921 $42.6 Million
Q3 2022 Nov 14, 2022	BUY	$29.63 - $48.31 $11.9 Million - $19.4 Million	400,922 New	400,922 $14 Million
Q2 2022 Aug 15, 2022	SELL	$27.79 - $50.61 $490,993 - $894,177	-17,668 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$39.62 - $69.97 $81.5 Million - $144 Million	-2,056,804 Reduced 99.15%	17,668 $828,000
Q1 2022 May 16, 2022	BUY	$39.62 - $69.97 $82.2 Million - $145 Million	2,074,472 New	2,074,472 $154 Million

295

91.1M

155K

426K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $1.96B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Rokos Capital Management LLP, based on Form 13F filings with the SEC.

Stay updated on Rokos Capital Management LLP with notifications on news.